Cirius Therapeutics
Cirius Therapeutics is a clinical-stage pharmaceutical company dedicated to developing innovative therapies for diseases caused by insulin resistance, including Type 2 Diabetes and Obesity. Their focus is on restoring insulin response and re-balancing mitochondrial metabolism to improve glycemic control, increase lean muscle mass, and shift fat tissue to more metabolically beneficial forms. They are advancing a next-generation oral insulin sensitizer, azemiglitazone (MSDC-0602K), which targets the mitochondrial pyruvate carrier (MPC) to address metabolic dysfunction at its root.
Industries
Nr. of Employees
small (1-50)
Cirius Therapeutics
Products
Once-daily oral MPC-targeting insulin sensitizer (small molecule)
A once-daily oral small-molecule therapeutic designed to modulate the mitochondrial pyruvate carrier to improve insulin sensitivity, glycemic control, reduce fatty liver, and favorably alter body composition.
Once-daily oral MPC-targeting insulin sensitizer (small molecule)
A once-daily oral small-molecule therapeutic designed to modulate the mitochondrial pyruvate carrier to improve insulin sensitivity, glycemic control, reduce fatty liver, and favorably alter body composition.
Services
Collaborative preclinical and translational research partnerships
Collaborations with academic laboratories to perform mechanistic preclinical studies and combination-therapy evaluations in metabolic disease models.
Collaborative preclinical and translational research partnerships
Collaborations with academic laboratories to perform mechanistic preclinical studies and combination-therapy evaluations in metabolic disease models.
Expertise Areas
- Insulin resistance therapeutics
- Metabolic disease drug development (T2D, obesity, MASH)
- Preclinical pharmacology and translational studies
- Clinical trial design and execution (Phase 2b, Phase 3 readiness)
Key Technologies
- Mitochondrial pyruvate carrier (MPC) targeting
- Oral small-molecule insulin sensitizers
- Preclinical rodent models (db/db mice)
- Biomarker assessment (HbA1c, fasting insulin, liver histology)